Business Context and Reporting Period
This Form 8-K is a current report filed by Sunshine Heart, Inc. (not Nuwellis, Inc.) on April 24, 2017. The filing announces the closing of an underwritten public offering of common stock, warrants, and Series E Convertible Preferred Stock.
Key Financial Metrics
- Gross Proceeds: $9.2 million (prior to deducting underwriting discounts, commissions, and offering expenses).
- Capital Raised Structure:
- 2,800,000 shares of Common Stock.
- 9,200,000 Common Stock Purchase Warrants.
- 6,400 shares of Series E Convertible Preferred Stock.
- Outstanding Equity (as of April 24, 2017):
- 7,379,865 shares of Common Stock.
- 4,940 shares of Series E Convertible Preferred Stock.
- Pending Conversions: Notices received to convert an additional 710 shares of Series E Convertible Preferred Stock into 710,000 shares of Common Stock.
Note: The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity beyond the proceeds from this specific offering.
Material Changes
The primary material change is the increase in capitalization and outstanding share count resulting from the closing of the public offering. The offering included the full exercise of the underwriter's over-allotment option. Additionally, certain Class B Unit holders elected to convert underlying Series E Convertible Preferred Stock into Common Stock prior to the closing.
Outlook, Risks, and Unusual Items
- Warrant Agency: The Company entered into a Warrant Agency Agreement with American Stock Transfer & Trust Company, LLC to serve as the Warrant Agent.
- Reference Documents: Detailed terms of the offering are contained in the Company's Registration Statement on Form S-1 (File No. 333-216841), declared effective on April 18, 2017.
- Risks/Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard execution of the offering and pending share conversions.
Investor Verification Checklist
- Verify the net proceeds after deducting underwriting discounts and offering expenses (gross proceeds are $9.2 million).
- Confirm the final share count once the pending conversion of 710 Series E shares is processed.
- Review the terms of the 9,200,000 Warrants issued in the offering.
- Examine the Form S-1 (File No. 333-216841) for detailed use of proceeds and risk factors.